Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Centro de investigación de vanguardia en OncologíaManzano 343, Recoleta, Región Metropolitana, Santiago
Websitehttp://bradfordhill.cl/
Select an option
I am a doctor
I am a sponsor
Specializations
Carcinoma de células renales
Cáncer
Cáncer de hígado
Cáncer de mama
Cáncer de próstata
Cáncer de pulmón
Neumonía
Melanoma
Cáncer de las vías biliares
Carcinoma hepatocelular
Cáncer de origen primario desconocido
Cáncer de vejiga
Cáncer de riñón
Our team
Medical staff
Carlos Rojas
Mauricio Burotto Pichun
Isabel Saffie
Bárbara Vivanco
Open studies
Lung cancer
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) - KEYVIBE-006 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) - Merck Sharp & Dohme LLCSee more
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
Prostate cancer
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) - MK-5684-003 - Merck Sharp & Dohme LLCSee more
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) - Merck Sharp & Dohme LLCSee more
Skin cancer
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma - RELATIVITY-127 - Bristol-Myers SquibbSee more
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma - Regeneron PharmaceuticalsSee more
Advanced tumors
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) - MK-1084-001 - Merck Sharp & Dohme Corp.See more
Colorectal cancer
A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) - Merck Sharp & Dohme LLCSee more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Esophageal cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) - LEAP-014 - Merck Sharp & Dohme Corp.See more
Lymphoma
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) - CC-99282-NHL-001 - CelgeneSee more
Myeloproliferative syndromes
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) - Merck Sharp & Dohme LLCSee more
